Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi

New England Journal of Medicine, 2011

Massachusetts General Hospital, Harvard University, Institut de Cancérologie de l'Ouest, Institut Jules Bordet, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Novartis (United States), Osaka University, Medical University of Vienna, Comprehensive Cancer Center Vienna, Sunnybrook Health Science Centre, University of Toronto, Highlands Oncology Group, Japanese Foundation For Cancer Research, Sarah Cannon Research Institute, Sarah Cannon, Vlaamse Vereniging voor Obstetrie en Gynaecolo, Memorial Healthcare System, Centre Léon Bérard, Novartis (Switzerland), The University of Texas MD Anderson Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2811

Citations

View on Google Scholar

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back